Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + TQB2450 +/- Anlotinib in PD-1 Resistant Digestive System Tumors
NCT04611711Phase 2Unknown
- Sponsor
- Peking University
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of benmelstobart in digestive system tumours (2 arms), sponsored by Peking University. Primary endpoint: Overall response rate up to 48 weeks. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
digestive system tumours
Beyond the preview
Go deeper on NCT04611711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611711.